A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Exclusion Criteria

• •Has one of the following tumor locations/types:
• •* NSCLC involving the superior sulcus
• •* Large cell neuro-endocrine cancer (LCNEC)
• •* Sarcomatoid tumor
• •* Diagnosis of SCLC or, for mixed tumors, presence of small cell elements
• •Has Grade ≥2 peripheral neuropathy
• •Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
• •Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
• •Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QT corrected for heart rate by Fridericia's cube root formula (QTcF) interval to \>480 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
• •Has received prior neoadjuvant therapy for their current NSCLC diagnosis
• •Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention
• •Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids
• •Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
• •Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration
• •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
• •Has a known additional malignancy that is progressing or has required active treatment within the past 5 years
• •Has an active autoimmune disease that has required systemic treatment in the past 2 years
• •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• •Has an active infection requiring systemic therapy
• •Is an HIV-infected participant with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
• •Has a concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection
• •Has a history of allogeneic tissue/solid organ transplant
• •Has not adequately recovered from major surgery or have ongoing surgical complications
• •Severe hypersensitivity (≥Grade 3) to study intervention, any of its excipients, and/or to another biologic therapy